Literature DB >> 29372387

Myasthenia gravis and infectious disease.

Nils Erik Gilhus1,2, Fredrik Romi3, Yu Hong4, Geir Olve Skeie3.   

Abstract

BACKGROUND AND
PURPOSE: Myasthenia gravis (MG) is an autoimmune disease with muscular weakness as the only symptom, and often with immunosuppressive treatment. All these aspects could have relevance for the risk of infections as well as their prophylactic and curative treatment.
METHODS: This is a review article, where Web of Science has been searched for relevant key words and key word combinations. Full papers were selected first by title and then by abstract. RESULTS AND
CONCLUSIONS: MG can be triggered and worsened by infections. No virus or other pathogen has been proven to have a specific link to MG. Treatment with immunosuppressive drugs and thymectomy implies a slightly increased risk for infections. Infections should be actively treated, but a few antibiotics are avoided due to potential interference with neuromuscular transmission. Hospitalization and intensive care may be necessary during infections because of MG deterioration and risk of insufficient respiration. Vaccinations are generally recommended in MG, but live microorganisms should be avoided if possible in immunosuppressed patients.

Entities:  

Keywords:  Antibiotics; Autoimmunity; Immunosuppression; Infection; Myasthenia gravis; Thymus; Vaccination

Mesh:

Year:  2018        PMID: 29372387     DOI: 10.1007/s00415-018-8751-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  79 in total

1.  Myasthenia gravis exacerbation or unmasking associated with telithromycin treatment.

Authors:  X Perrot; N Bernard; C Vial; J C Antoine; H Laurent; T Vial; C Confavreux; S Vukusic
Journal:  Neurology       Date:  2006-10-25       Impact factor: 9.910

2.  Effect of thymectomy on human peripheral blood T cell pools in myasthenia gravis.

Authors:  G Sempowski; J Thomasch; M Gooding; L Hale; L Edwards; E Ciafaloni; D Sanders; J Massey; D Douek; R Koup; B Haynes
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

3.  Eculizumab: a treatment option for myasthenia gravis?

Authors:  Nils Erik Gilhus
Journal:  Lancet Neurol       Date:  2017-10-20       Impact factor: 44.182

4.  Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection.

Authors:  Paola Cavalcante; Barbara Galbardi; Sara Franzi; Stefania Marcuzzo; Claudia Barzago; Silvia Bonanno; Giorgia Camera; Lorenzo Maggi; Dimos Kapetis; Francesca Andreetta; Amelia Biasiucci; Teresio Motta; Carmelo Giardina; Carlo Antozzi; Fulvio Baggi; Renato Mantegazza; Pia Bernasconi
Journal:  Immunobiology       Date:  2015-12-12       Impact factor: 3.144

Review 5.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms.

Authors:  Sonia Berrih-Aknin; Rozen Le Panse
Journal:  J Autoimmun       Date:  2014-01-03       Impact factor: 7.094

6.  EBV Infection Empowers Human B Cells for Autoimmunity: Role of Autophagy and Relevance to Multiple Sclerosis.

Authors:  Elena Morandi; S Anwar Jagessar; Bert A 't Hart; Bruno Gran
Journal:  J Immunol       Date:  2017-06-07       Impact factor: 5.422

Review 7.  Fluoroquinolone-associated myasthenia gravis exacerbation: evaluation of postmarketing reports from the US FDA adverse event reporting system and a literature review.

Authors:  S Christopher Jones; Alfred Sorbello; Robert M Boucher
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

8.  Myasthenia gravis: another autoimmune disease associated with hepatitis C virus infection.

Authors:  S Eddy; R Wim; V E Peter; R Tanja; T Jan; V S Werner
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

Review 9.  Antiviral immune responses: triggers of or triggered by autoimmunity?

Authors:  Christian Münz; Jan D Lünemann; Meghann Teague Getts; Stephen D Miller
Journal:  Nat Rev Immunol       Date:  2009-04       Impact factor: 53.106

10.  Associations between selected immune-mediated diseases and tuberculosis: record-linkage studies.

Authors:  Sreeram V Ramagopalan; Raph Goldacre; Andrew Skingsley; Chris Conlon; Michael J Goldacre
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

View more
  33 in total

1.  Favipiravir Experience in Covid-19 Positive Myasthenia Gravis Patients.

Authors:  Recep Yevgi; Nuray Bilge; Fatma Şimşek
Journal:  Eurasian J Med       Date:  2021-06

2.  User Involvement in Myasthenia Gravis Research.

Authors:  Nils Erik Gilhus; Sandra Iren Barkås Hovland
Journal:  Front Neurol       Date:  2022-06-02       Impact factor: 4.086

3.  Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report.

Authors:  Min Chae Kang; Kyung-Ah Park; Ju-Hong Min; Sei Yeul Oh
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-25

4.  COVID-19 infection and vaccination against SARS-CoV-2 in myasthenia gravis.

Authors:  Stojan Peric; Milos Rankovic; Ivo Bozovic; Vanja Radosavljevic; Ivan Marjanovic; Ivana Basta; Dragana Lavrnic
Journal:  Acta Neurol Belg       Date:  2022-10-24       Impact factor: 2.471

5.  COVID-19 in patients with myasthenia gravis: Epidemiology and disease course.

Authors:  Pietro Businaro; Gloria Vaghi; Enrico Marchioni; Luca Diamanti; Sebastiano Arceri; Paola Bini; Elena Colombo; Giuseppe Cosentino; Enrico Alfonsi; Alfredo Costa; Sabrina Ravaglia; Giulia Mallucci; Elena Ballante; Diego Franciotta; Matteo Gastaldi
Journal:  Muscle Nerve       Date:  2021-06-12       Impact factor: 3.852

6.  A Systematic Review of the Potential Implication of Infectious Agents in Myasthenia Gravis.

Authors:  Victoria Leopardi; Yu-Mei Chang; Andrew Pham; Jie Luo; Oliver A Garden
Journal:  Front Neurol       Date:  2021-06-14       Impact factor: 4.003

Review 7.  Myasthenia Gravis Can Have Consequences for Pregnancy and the Developing Child.

Authors:  Nils Erik Gilhus
Journal:  Front Neurol       Date:  2020-06-12       Impact factor: 4.003

8.  COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.

Authors:  Swathi Beladakere Ramaswamy; Raghav Govindarajan
Journal:  J Neuromuscul Dis       Date:  2020

Review 9.  Insights into Thymus Development and Viral Thymic Infections.

Authors:  Francesco Albano; Eleonora Vecchio; Maurizio Renna; Enrico Iaccino; Selena Mimmi; Carmen Caiazza; Alessandro Arcucci; Angelica Avagliano; Valentina Pagliara; Giuseppe Donato; Camillo Palmieri; Massimo Mallardo; Ileana Quinto; Giuseppe Fiume
Journal:  Viruses       Date:  2019-09-09       Impact factor: 5.048

10.  COVID-19 in patients with myasthenia gravis.

Authors:  Pria Anand; Michaël C C Slama; Michelle Kaku; Charlene Ong; Anna M Cervantes-Arslanian; Lan Zhou; William S David; Amanda C Guidon
Journal:  Muscle Nerve       Date:  2020-05-22       Impact factor: 3.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.